FDA has approved a new drug having active ingredient lifitegrast with brand name of Xiidra for the treatment of dry eye disease. This drug belongs to class termed as lymphocyte function-associated antigen 1 (LFA-1) antagonist. This is first kind of drug of its class approved for the treatment of dry eye disease. This drug is presented to FDA in the form of ophthalmic solution and marked as prescription only medicine.
Dryness of eyes is a common problem in elder people due to decrease activity of tears gland. Dryness of eye itself does cause any harm or damage to eye but it increases the risk of eye ulcer, corneal injury, difficulty in blinking, vision problem etc. About 5% of individuals having age 30 to 40 years have problem of dryness of eyes while people with age more than 65 years have 10% occurrence rate.
Most common reasons of eye dryness is inadequate production of tears or low consistency of ophthalmic fluid. These problem may arise due to extreme weather conditions like extreme hot or cold weather or too much air pressure.
About 1100 individuals were selected to assess the clinical efficacy and safety profile of Xiidra/lifitegrast. It shows satisfactory results in four randomized controlled clinical trials. During these clinical trials patients received lifitegrast eyedrops or placebo eyedrops twice daily 12 hours apart for 12 weeks.
Xiidra/lifitegrast Side EffectsDuring clinical trials most common side effects observed were mild to moderate but there was no evidence of serious kind of side effects. Some common side effects were
- Eye irritation
- Blurred vision
- Dysgeusia (Feeling unusual taste)
- Burning sensation